N-benzyl-2-{(4S)-4-[(5-bromo-1H-indol-3-yl)methyl]-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl}-N-isopropylacetamide | 1257822-08-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-benzyl-2-{(4S)-4-[(5-bromo-1H-indol-3-yl)methyl]-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl}-N-isopropylacetamide
• CAS: 1257822-08-4
• 化学式: C₃₇H₃₃BrN₆O₂
• 分子量: 673.612
• InChiKey: NDDYAHXIWOJFJE-PMERELPUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.29
• 重原子数：
  46.0
• 可旋转键数：
  8.0
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  87.12
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  N-benzyl-2-{(4S)-4-[(5-bromo-1H-indol-3-yl)methyl]-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl}-N-isopropylacetamide 在 palladium 10% on activated carbon 、 氢气 、 甲酸铵 作用下， 以 甲醇 为溶剂， 以26 mg的产率得到CE-326597
  参考文献：
  名称：

  Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity

  摘要：

  We describe the design, synthesis, and structure-activity relationships of triazolobenzodiazepinone CCK1 receptor agonists. Analogs in this series demonstrate potent agonist activity as measured by in vitro and in vivo assays for CCK1 agonism. Our efforts resulted in the identification of compound 4a which significantly reduced food intake with minimal systemic exposure in rodents. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.08.115
• 作为产物：
  描述：

  N-benzyl-2-(4-((5-bromo-1H-indol-3-yl)methylene)-5-oxo-1-phenyl-4,5-dihydro-6H-benzo[b][1,2,4]triazolo[4,3-d][1,4]diazepin-6-yl)-N-isopropylacetamide 在 溶剂黄146 、 锌 作用下， 反应 48.0h， 以1.16 g的产率得到N-benzyl-2-{(4S)-4-[(5-bromo-1H-indol-3-yl)methyl]-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl}-N-isopropylacetamide
  参考文献：
  名称：

  Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity

  摘要：

  We describe the design, synthesis, and structure-activity relationships of triazolobenzodiazepinone CCK1 receptor agonists. Analogs in this series demonstrate potent agonist activity as measured by in vitro and in vivo assays for CCK1 agonism. Our efforts resulted in the identification of compound 4a which significantly reduced food intake with minimal systemic exposure in rodents. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.08.115